Internal medicine

Pathology

Archaeology

Placebo

Biology

History

Cancer

Surgery

Oncology

Stage (stratigraphy)

Paleontology

Randomization

Randomized controlled trial

Alternative medicine

Paclitaxel

Vigil

Chemotherapy

Cisplatin

Carboplatin

Ovarian cancer

Debulking

Medicine

Obstetrical & Gynecological Survey

(Abstracted from Lancet Oncol 2020;21:1661–1672) Standard-of-care treatment for stages III and IV newly diagnosed ovarian cancer involves primary debulking surgery followed by adjuvant paclitaxel and carboplatin or neoadjuvant chemotherapy with interval debulking surgery. Despite this protocol commonly resulting in complete remission, approximately 75% of patients will relapse within 2 years.

Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial